Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Acifran (antihyperlipoproteinemic), Ayerst Acyclovir sodium (antiviral), Zovirax, Burroughs Wellcome Adinazolam mesylate (antidepressant),Deracyn, Upjohn Alfuzosin HCI (antihypertensive; alpha-blocker), Synthelabo Altanserin tartrate (serotonin antagonist), Janssen Amifloxacin (antibacterial), Sterling Amifloxacin mesylate (antibacterial), Sterling Anirolac (anti-inflammatory; analgesic), Syntex Arclofenin (diagnostic aid; hepatic function determination), Merck Frosst Azaloxan fumarate (antidepressant), Ciba Geigy Azelastine HCI (anti-allergic; anti-asthmatic), Degussa A.G.m, Wallace Biclodil HCI (antihypertensive; vasodilator), Rorer Bipenamol HCI (antidepressant), Burroughs Wellcome Brocrinat (diuretic), Hoechst-Roussel Carumanam sodium (antibacterial), Roche Cerbuperazone (antibacterial), Bristol-Myers Cefpimizole (antibacterial), Upjohn Cefpimzole sodium (antibacterial), Upjohn Cellulose sodium phosphate (anti-urolithic), Calcibind, Mission Pharmacal Cetirizeine HCI (antihistaminic), Pfizer Cicloprolol HCI (beta blocker), Synthelabo Ciladopa HCI (antiparkinsonian; dopaminergic agent), Ayerst Cinflumide (muscle relaxant), Burroughs Wellcome Ciprostene calcium (platelet anti-aggregatory agent), Upjohn Ciramadol HCI (analgesic), Cindol, Wyeth Cloticasone propionate (anti-inflammatory), Glaxo Coumermycin sodium (antibacterial), Roche Dazmegrel (thromboxane synthetase inhibitor) Pfizer Deltafilcon B (contact lens material; hydorphilic), Lombart Doperxamine (cardiovascular agent), Fisons Dronabinol (anti-emetic), Marinol, Unimed; Sisacian, PARS Edoxudine (antiviral), Ortho Enpiroline phosphate (anitmalarial), Walter Reed Army Institute of Research Epirubicin HCI (antineoplastic), Adria, Farmitalia Carlo Erba Epsotane (interceptive), Sterling Famotidine (H]2[ antagonist), Merck Fenretinide (antineoplastic), McNeil Fentiazac (anti-inflammatory), Wyeth Flestolol sulfate (beta blocker), American Critical Care Fluorometholone acetate (anti-inflammatory) Upjohn Flupirtine maleate (analgesic), Degussa A.G., Wallace Fluticasone propionate (anti-inflammarory), Glaxo FocofilconA (contact lens material; hydorphilic), Fre-Flex, Optech Foscarnet sodium (antiviral), Astra Fumoxicillin (antibacterial), Farmats S.R.L. Gepirone HCI (tranquilizer), Bristol Myers Histerlin (LHRH analog), Ortho Imiloxan HCI (antidepressant), Syntex Indium 111 Oxyquinoline (radioactive agent; diagnostic aid), Medi-Physics Indoramin HCI (antihypertensive), Wyeth Iofetamine HCI I 123 (radioactive agent; diagnostic aid), Perfusamine, Medi-Physics Itraconazole (antifungal), Janssen Ketorolac tromethamine (analgesic), Synthex Levocabastine HCI (antihistaminic), Janssen Lobenzarit sodium (antirheumatic), Chugai Pharmeceutical Losulazine HCI (antihypertiensive), Upjohn Lupitidine HCI (H]2[ antagonist; veterinary), SK&F Mecetronium ethysulfate (antiseptic), Bacillofabrick Dr. Bode & Co. Mefloquine HCI (analgesic), Lariam, Roche Meptazinol HCI (analgesic), Wyeth, Ives Minocromil (anti-allergy prophylactic), Fisons Nedocromil (anti-allergy prophylactic), Fisons Nedocromil sodium (anti-allergy prophylactic), Fisons Nicotine polocrilex (smoking detergent), Nicorette, Merrell Dow Nilvadipine (calcium channel blocker), Fujisawa Octenidine saccharin (dental plaque inhibitor), Sterling Ofloxacin (antibacterial), Daiichi Seiyaku Ofornine (antihypertensive), Sterling Pelrinone HCI (cardiotonic), Ayerst Pentopril (antiotenbsin converting enzyme inhibitor), Ciba Geigy Pinadoline (analgesic), Searle Piquindone HCI (antipsychotic), Roche Piriprost (anti-asthmatic), Upjohn Piriprost potassium (anti-asthmatic), Upjohn Pirmagrel (thromboxane synthetase inhibitor), Ciba Geigy Piroxicam olamine (analgesic; anti-inflammatory), Pfizer Piroximone (cardiotonic), Merrell Dow Pivopril (antihypertensive), USV Polybutester (surgical suture materil), Novafil, Davis & Geck Progabide (anticonvulsant; muscle relaxant), Gabren, Synthelabo Quadazocine mesylate (opioid antagonist), Sterling Quazinone (cardiotonic), Posicor, Roche Quinapril HCI (angiotensin converting enzyme inhibitor), Parke-Davis Quinpirole HCI (antihypertensive), Lilly Remoxipride (antipsychotic), Astra Rifapentine (antibacterial), Merrell Dow Ristianol phosphate (immunoregulator), Pfizer Ritanserin (serotonin antagonist), Janssen Setoperone (antipsychotic), Janssen Somatrem (growth hormone), Protropin, Genentech Sufentanil citrate (narcotic analgesic), Sufenta, Janssen Suproclone (sedative), Rhone-Poulec Tazadolene succinate (anlagesic), Upjohn Tazifylline HCI (antihistaminic), Syntex Tiacrilast (anti-allergic), Roche Tiapamil HCI (calcium channel blocker), Roche Timolol (beta blocker), Merck Tolrestat (aldose reductase inhibitor), Ayerst Tranilast (anti-asthmatic), Kissei Pharmaceutical Transcainide (cardiac depressant; anti-arrhythmic), Jenssen Trientine HCI (Wilson's disease, therapy adjunct), Merck Trifenagrel (antithrombotic), Burroughs Wellocome Trospectomycin sulfate (antibacterial), Upjohn Vigabatrin (anticonvulsant; tardive dyskinesia), Merrell Dow Zofenopril calcium (angiotensin converting enzyme inhibitor), Squibb Zonisamide (anticonvulsant), Parke-Davis

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts